UbiquiTx, Inc.

UbiquiTx is pleased to announce that we have been selected as the 2024 Eddies Winner in the Biotech category by the Massachusetts Innovation Network! #2024Eddies https://lnkd.in/gCpdPxmd

UbiquiTx is proud to announce that it has recently been awarded a NYSTAR Innovation Matching Grant to support its recently awarded NIH SBIR Award (Chimeric Ligands for Induced Proximity platform targeted proteome editing and upregulation of antigen presentation) with collaborator Memorial Sloan Kettering and further drive innovation in New York State! https://lnkd.in/eYbtxVjj

Congrats?to UbiquiTx co-founders Matthew DeLisa (@DeLisaGroup) and Pranam Chatterjee (@pranamanam) on their recent publication demonstrating the power of differentiated sequenced-based AI peptide design and modular ubiquibodies paving the way for a new therapeutic platform of next-generation protein modulation! @Targetedproteindegradation Paper: https://lnkd.in/eNdRwmWV

UbiquiTx is proud to announce its acceptance into the latest cohort of the Merck Digital Sciences Studio (MDS Studio), a digital accelerator designed to enable the next generation of technologies for drug discovery and development, including artificial intelligence and machine learning. MDS Studio was founded to offer support for early-stage biomedical startups providing strategic guidance, direct investment, and connection?opportunities?within Merck.

UbiquiTx, Inc. is pleased to announce that it has been awarded a NIH National Institute of Allergy and Infectious Disease Phase I STTR grant for Chimeric Ligands for Induced Proximity (CLIP) platform for targeted proteome editing and upregulation of antigen presentation.?? #NIAID, #NIH, #EndlessFrontier

UbiquiTx, Inc. is pleased to announce it has been awarded a National Science Foundation (NSF) Phase I SBIR grant for Chimeric Ligands for Induced Proximity (CLIPs) for Targeted Proteome Editing. #NSF, #EndlessFrontier, #Targetedproteinediting https://lnkd.in/eNwVDJgr

UbiquiTx is pleased to announce that it has been selected as an Eddies finalist by the Massachusetts Innovation Network. For more information, see below:

UbiquiTx, in partnership with Cornell University, has been award an National Institute for General Medicine Sciences (NIGMS) Phase 1 STTR grant for computational design and evaluation of peptide-guided protein degraders. #UbiquiTx, #Endlessfronteirlabs, #proteindegraders

Exciting News! UbiquiTx is thrilled to announce our participation in @MassBio? 2024 Align Summit with insights by @McKinsey and @LocustWalk. We'll be showcasing our?groundbreaking work in Biotech/AI-ML on April 25 at the Royal Sonesta Hotel. Join us for a day filled?with partnering, keynotes, panel discussions and presentations from other innovative seed/series A? #biotech and emerging artificial intelligence/machine learning companies.? Register here: https://lnkd.in/euynZvkA #AlignSummit24 #AlignSummit #AIDrugDiscovery